Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

globenewswire

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN<img src=”https://s.w.org/images/core/emoji/16.0.1/72×72/2122.png” alt=”™” class=”wp-smiley”> Rapamycin for Cutaneous Venous Malformations – NEWSnet – News… as it used to be